Joris Beld

Dr. Joris Beld


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
JCJiandong Chen
Jiandong Chen
HBHyuntae Byun
Hyuntae Byun
RLRui Liu
Rui Liu
IJI-Ji Jung
I-Ji Jung
QPQinqin Pu
Qinqin Pu
JZJun Zhu
Jun Zhu
Significance: In a polymicrobial battlefield where different species compete for nutrients and colonization niches, antimicrobial compounds are the sword and shield of commensal microbes in competition with invading pathogens and each other. The identification of an Escherichia coli –produced genotoxin, colibactin, and its specific targeted killing of enteric pathogens and commensals, including Vibrio cholerae and Bacteroides fragilis , sheds light on our understanding of intermicrobial interactions in the mammalian gut. Our findings elucidate the mechanisms through which genotoxins shape microbial communities and provide a platform for probing the larger role of enteric multibacterial interactions regarding infection and disease outcomes.

15 August 2008 in Biochemistry
Verified
Journal Article
Closed access
DSDaniel Steinmann
Daniel Steinmann
TNThomas Nauser
Thomas Nauser
JBJoris Beld
Joris Beld
MTMartin Tanner
Martin Tanner
DGDetlef Günther
Detlef Günther
WKWillem H. Koppenol
Willem H. Koppenol

1 March 2021 in Biotechnology Reports
Verified
Journal Article
Open access
HMHaley M. Majer
Haley M. Majer
RERachel L. Ehrlich
Rachel L. Ehrlich
AAAzad Ahmed
Azad Ahmed
JEJoshua P. Earl
Joshua P. Earl
GEGarth D. Ehrlich
Garth D. Ehrlich
JBJoris Beld
Joris Beld
• Whole genome sequencing of Actinomycetes reveals metabolic potential. • High quality genomes are necessary for mining of biosynthetic gene clusters. • Characterization of thiopeptides by high resolution mass spectrometry. • Thiopeptides are potent antibacterials against Staphylococcus aureus.

20 October 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MCMadeline F. Currie
Madeline F. Currie
DPDylan M. Persaud
Dylan M. Persaud
NRNiralee K. Rana
Niralee K. Rana
APAmanda J. Platt
Amanda J. Platt
JBJoris Beld
Joris Beld
KJKara L. Jaremko
Kara L. Jaremko
Fatty acids are essential to most organisms and are made endogenously by the fatty acid synthase (FAS). FAS is an attractive target for antibiotics and many inhibitors are in clinical development. However, some gram-negative bacteria harbor an enzyme known as the acyl-acyl carrier protein synthetase (AasS), which allows them to scavenge fatty acids from the environment and shuttle them into FAS and ultimately lipids. The ability of AasS to recycle fatty acids may help pathogenic gram-negative bacteria circumvent FAS inhibition. We therefore set out to design and synthesize an inhibitor of AasS and test its effectiveness on an AasS enzyme fromVibrio harveyi, the most well studied AasS to date, and fromVibrio cholerae, a pathogenic model. The inhibitor C10-AMS [5′-O-(N-decanylsulfamoyl)adenosine], which mimics the tightly bound acyl-AMP reaction intermediate, was able to effectively inhibit AasS catalytic activity in vitro. Additionally, C10-AMS stopped the ability ofVibrio choleraeto recycle fatty acids from media and survive when its endogenous FAS was inhibited with cerulenin. C10-AMS can be used to study fatty acid recycling in other bacteria as more AasS enzymes continue to be annotated and provides a platform for potential antibiotic development.

2 January 2025 in ACS Chemical Biology
Verified
Journal Article
Open access
KLKevin Li
Kevin Li
YCYae In Cho
Yae In Cho
MTMai Anh Tran
Mai Anh Tran
CWChristoph Wiedemann
Christoph Wiedemann
SZShuaibing Zhang
Shuaibing Zhang
LCLouise K. Charkoudian
Louise K. Charkoudian
Microbial polyketides represent a structurally diverse class of secondary metabolites with medicinally relevant properties. Aromatic polyketides are produced by type II polyketide synthase (PKS) systems, each minimally composed of a ketosynthase-chain length factor (KS-CLF) and a phosphopantetheinylated acyl carrier protein (holo-ACP). Although type II PKSs are found throughout the bacterial kingdom, and despite their importance to strategic bioengineering, type II PKSs have not been well-studied in vitro. In cases where the KS-CLF can be accessed via E. coli heterologous expression, often the cognate ACPs are not activatable by the broad specificity Bacillus subtilis surfactin-producing phosphopantetheinyl transferase (PPTase) Sfp and, conversely, in systems where the ACP can be activated by Sfp, the corresponding KS-CLF is typically not readily obtained. Here, we report the high-yield heterologous expression of both cyanobacterial Gloeocapsa sp. PCC 7428 minimal type II PKS (gloPKS) components in E. coli, which allowed us to study this minimal type II PKS in vitro. Initially, neither the cognate PPTase nor Sfp converted gloACP to its active holo state. However, by examining sequence differences between Sfp-compatible and -incompatible ACPs, we identified two conserved residues in gloACP that, when mutated, enabled high-yield phosphopantetheinylation of gloACP by Sfp. Using analogous mutations, other previously Sfp-incompatible type II PKS ACPs from different bacterial phyla were also rendered activatable by Sfp. This demonstrates the generalizability of our approach and breaks down a longstanding barrier to type II PKS studies and the exploration of complex biosynthetic pathways.

21 September 2021 in Applied Microbiology and Biotechnology
Verified
Journal Article
Closed access
PDF file
CJCourtney V. Jones
Courtney V. Jones
BJBrianna G. Jarboe
Brianna G. Jarboe
HMHaley M. Majer
Haley M. Majer
AMAmy T. Ma
Amy T. Ma
JBJoris Beld
Joris Beld